China’s Health Care Reform Begs Key Questions
This article was originally published in PharmAsia News
Executive Summary
Analysts believe that China's RMB 850 billion injection into its health care reform will have a positive effect during the current financial crisis. However, Beijing University's director in the China medicine economics research center points out that three questions remain that need to be addressed. The first is the lack of regulatory details on the spending areas. The second is the omission of the avenues of disbursement. The previous program used a top-down distribution model that did not achieve the desired results, thus there needs to be a market approach that reimburses the public directly. Third is the lack of clarification on how to solve the issue of medical services not meeting demand. (Click here for more - Chinese Language)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.